Side effects, cost, supply, target: four reasons with four trajectories
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
Shortage listings
Page 4 of 13 of this archive, newest first.
A shortage listing ends. 21 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Maintenance dosing: what is licensed, what is practised, and what is evidenced
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
The 25-day notice: how a compounding wind-down works in Denmark
The document is four pages. Three of them are about dates.
The supply gap as a clinical event
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
The 21-day notice: how a compounding wind-down works in India
The document is four pages. Three of them are about dates.
A shortage listing ends. 7 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The 22-day notice: how a compounding wind-down works in India
The document is four pages. Three of them are about dates.
A shortage listing ends. 11 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
A shortage listing ends. 11 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
A shortage listing ends. 13 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The 25-day notice: how a compounding wind-down works in Poland
The document is four pages. Three of them are about dates.
A shortage listing ends. 20 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The lowest effective dose is a real concept with almost no data behind it
The commonest real-world strategy in this drug class is the least studied one.
The 26-day notice: how a compounding wind-down works in Italy
The document is four pages. Three of them are about dates.
The 12-day notice: how a compounding wind-down works in Saudi Arabia
The document is four pages. Three of them are about dates.
Why people actually stop, in the order they actually stop
Why the reason for stopping changes what happens afterwards.
The 25-day notice: how a compounding wind-down works in India
The document is four pages. Three of them are about dates.
A shortage listing ends. 7 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The 28-day notice: how a compounding wind-down works in India
The document is four pages. Three of them are about dates.